CoChat
Sign Up
Cited by 297Parkinson's Disease Mechanisms and TreatmentsNerve injury and regenerationVirus-based gene therapy research

Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease

Open access
Bilang-Bleuel, Alicia, Revah, Frédéric, Colin, Phillippe, Locquet, Isabelle, Robert, Jean-Jacques, Mallet, Jacques, Horellou, Philippe·1997·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.94.16.8818PMC PMC23145
Open this paper in CoChat — free account

Abstract

Glial-cell-line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor for adult nigral dopamine neurons in vivo . GDNF has both protective and restorative effects on the nigro-striatal dopaminergic (DA) system in animal models of Parkinson disease. Appropriate administration of this factor is essential for the success of its clinical application. Since it cannot cross the blood–brain barrier, a gene transfer method may be appropriate for delivery of the trophic factor to DA cells. We have constructed a recombinant adenovirus (Ad) encoding GDNF and injected it into rat striatum to make use of its ability to infect neurons and to be retrogradely transported by DA neurons. Ad-GDNF was found to drive production of large amounts of GDNF, as quantified by ELISA. The GDNF produced after gene transfer was biologically active: it increased the survival and differentiation of DA neurons in vitro . To test the efficacy of the Ad-mediated GDNF gene transfer in vivo , we used a progressive lesion model of Parkinson disease. Rats received injections unilaterally into their striatum first of Ad and then 6 days later of 6-hydroxydopamine. We found that mesencephalic nigral dopamine neurons of animals treated with the Ad-GDNF were protected, whereas those of animals treated with the Ad-β-galactosidase were not. This protection was associated with a difference in motor function: amphetamine-induced turning was much lower in animals that received the Ad-GDNF than in the animals that received Ad-β-galactosidase. This finding may have implications for the development of a treatment for Parkinson disease based on the use of neurotrophic factors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.94.16.8818

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intracerebral injections are clinically feasible and are performed in a variety of clinical scenarios and preclinical settings.

    “Intracerebral injections are clinically feasible, and are performed in a variety of clinical scenarios (17–23), as well as in various preclinical settings (4, 24–27).”

    From Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection (2023) · cites this paper as [24]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [1]Lin L F, Doherty D H, Lile J D, Bektesh S, Collins F. Science. 1993;260:1130–1132. doi: 10.1126/science.8493557. [DOI] [PubMed] [Google Scholar] · DOI
  2. [2]Hou J G, Lin L F, Mytilineou C. J Neurochem. 1996;66:74–82. doi: 10.1046/j.1471-4159.1996.66010074.x. [DOI] [PubMed] [Google Scholar] · DOI
  3. [3]Sauer H, Rosenblad C, Björklund A. Proc Natl Acad Sci USA. 1995;92:8935–8939. doi: 10.1073/pnas.92.19.8935. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  4. [4]Beck K D, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen R A, Rosenthal A, Hefti F. Nature (London) 1995;373:339–341. doi: 10.1038/373339a0. [DOI] [PubMed] [Google Scholar] · DOI
  5. [5]Tomac A, Widenfalk J, Lin L-F, Kohno T, Ebendal T, Hoffer B J, Olson L. Proc Natl Acad Sci USA. 1995;92:8274–8278. doi: 10.1073/pnas.92.18.8274. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  6. [7]Lin L F, Zhang T J, Collins F, Armes L G. J Neurochem. 1994;63:758–768. doi: 10.1046/j.1471-4159.1994.63020758.x. [DOI] [PubMed] [Google Scholar] · DOI
  7. [8]Le Gal La Salle G, Robert J J, Berrard S, Ridoux V, Stratford-Perricaudet L D, Perricaudet M, Mallet J. Science. 1993;259:988–990. doi: 10.1126/science.8382374. [DOI] [PubMed] [Google Scholar] · DOI
  8. [9]Horellou P, Vigne E, Castel M N, Barnéoud P, Colin P, Perricaudet M, Delaère P, Mallet J. NeuroReport. 1994;6:49–53. doi: 10.1097/00001756-199412300-00014. [DOI] [PubMed] [Google Scholar] · DOI
  9. [10]Ridoux V, Robert J J, Zhang X, Perricaudet M, Mallet J, Le Gal La Salle G. Brain Res. 1994;648:171–175. doi: 10.1016/0006-8993(94)91919-4. [DOI] [PubMed] [Google Scholar] · DOI
  10. [11]Sauer H, Oertel W H. Neuroscience. 1994;59:401–415. doi: 10.1016/0306-4522(94)90605-x. [DOI] [PubMed] [Google Scholar] · DOI
  11. [12]Stratford-Perricaudet L D, Makeh I, Perricaudet M, Briand P. J Clin Invest. 1992;90:626–630. doi: 10.1172/JCI115902. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  12. [13]Lundberg C, Horellou P, Mallet J, Björklund A. Exp Neurol. 1996;139:39–53. doi: 10.1006/exnr.1996.0079. [DOI] [PubMed] [Google Scholar] · DOI
  13. [14]Kozak M. Nucleic Acids Res. 1985;12:857–872. doi: 10.1093/nar/12.2.857. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  14. [15]Sabaté O, Horellou P, Vigne E, Colin P, Perricaudet M, Buc-Caron M H, Mallet J. Nat Genet. 1995;9:256–260. doi: 10.1038/ng0395-256. [DOI] [PubMed] [Google Scholar] · DOI
  15. [16]Ungerstedt U, Arbuthnott G W. Brain Res. 1970;24:485–493. doi: 10.1016/0006-8993(70)90187-3. [DOI] [PubMed] [Google Scholar] · DOI
  16. [17]Schaar D G, Sieber B A, Dreyfus C F, Black I B. Exp Neurol. 1993;124:368–371. doi: 10.1006/exnr.1993.1207. [DOI] [PubMed] [Google Scholar] · DOI
  17. [18]Bowenkamp K E, David D, Lapchak P L, Henry M A, Granholm A C, Hoffer B J, Mahalik T J. Exp Brain Res. 1996;111:1–7. doi: 10.1007/BF00229549. [DOI] [PubMed] [Google Scholar] · DOI
  18. [19]Winkler C, Sauer H, Lee C S, Björklund A. J Neurosci. 1996;16:7206–7215. doi: 10.1523/JNEUROSCI.16-22-07206.1996. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  19. [20]Hefti F, Melamed E, Wurtman R J. Brain Res. 1980;195:123–137. doi: 10.1016/0006-8993(80)90871-9. [DOI] [PubMed] [Google Scholar] · DOI
  20. [21]Heikkila R E, Shapiro B S, Duvoisin R C. Brain Res. 1981;195:123–137. doi: 10.1016/0006-8993(81)90614-4. [DOI] [PubMed] [Google Scholar] · DOI
  21. [22]Björklund A, Stenevi U. Brain Res. 1979;177:555–560. doi: 10.1016/0006-8993(79)90472-4. [DOI] [PubMed] [Google Scholar] · DOI
  22. [23]Hudson J L, van Horne C G, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer B J, Gerhardt G A. Brain Res. 1993;626:167–174. doi: 10.1016/0006-8993(93)90576-9. [DOI] [PubMed] [Google Scholar] · DOI
  23. [24]Tomac A, Lindqvist E, Lin L-F, Ogren S O, Young D, Hoffer B J, Olson L. Nature. 1995;373:335–339. doi: 10.1038/373335a0. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  24. [25]Choi-Lundberg D L, Lin Q, Mohajeri H, Chang Y N, Chiang Y L, Hay C M, Davidson B L, Bohn M C. Science. 1997;275:838–841. doi: 10.1126/science.275.5301.838. [DOI] [PubMed] [Google Scholar] · DOI
  25. [26]Byrnes A P, MacLaren R E, Charlton H M. J Neurosci. 1996;16:3045–3055. doi: 10.1523/JNEUROSCI.16-09-03045.1996. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  26. [27]Yeh P, Dedieu J F, Orsini C, Vigne E, Denèfle P, Perricaudet M. J Virol. 1996;70:559–565. doi: 10.1128/jvi.70.1.559-565.1996. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., & Horellou, P.
Affiliations
  • Unité Mixte de Recherche 9923, Centre National de la Recherche Scientifique, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Dégénératifs, Hôpital de la Pitié-Salpêtrière, Bâtiment CERVI, 83 Boulevard de l’Hôpital, 75013 Paris, France; and Rhône–Poulenc Rorer, GenCell, Centre de Recherches de Vitry-Alfortville, 13 Quai Jules Guesde, 94403 Vitry-sur-Seine, France
  • Centre National de la Recherche Scientifique (FR)
ORCID
Horellou, Philippe
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
1997-08-05
Volume
94
Issue
16
Pages
8818-8823
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.94.16.8818
PMC
PMC23145
OpenAlex
W2088827109
Cited by
297
References
1
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 4
FWCI
27.12
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
glial cell line-derived neurotrophic factor, Parkinson's disease, adenoviral vector, gene therapy, dopaminergic neuron survival, striatum, 6-hydroxydopamine lesion, nigrostriatal pathway, neurotrophic factors, motor function
MeSH terms
Adenoviridae, Animals, Behavior, Animal, Disease Models, Animal, Female, Genetic Vectors, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Genetic Therapy, Rats, Sprague-Dawley, Gene Transfer Techniques, Neuroprotective Agents, Glial Cell Line-Derived Neurotrophic Factor, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review